Downregulation of Ras GTPase‑activating protein 1 is associated with poor survival of breast invasive ductal carcinoma patients

Liu,Yang; Liu,Tong; Sun,Qian; Niu,Ming; Jiang,Yang; Pang,Da

doi:10.3892/or.2014.3604

Downregulation of Ras GTPase‑activating protein 1 is associated with poor survival of breast invasive ductal carcinoma patients

Authors:
- Yang Liu
- Tong Liu
- Qian Sun
- Ming Niu
- Yang Jiang
- Da Pang
View Affiliations

Affiliations: Department of Breast Surgery, The Affiliated Cancer Hospital, Harbin Medical University, Nangang, Harbin, Heilongjiang, P.R. China, Department of Pathology, The Affiliated Cancer Hospital, Harbin Medical University, Nangang, Harbin, Heilongjiang, P.R. China
Published online on: November 13, 2014 https://doi.org/10.3892/or.2014.3604
Pages: 119-124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ras GTPase‑activating protein 1 (RASA1) functions to inactivate Ras‑GTPase and inhibit the mitogenic signal. Reduction or loss of RASA1 expression occurs during human cancer development and progression. This study investigated RASA1 expression in normal and breast cancer tissue specimens to determine the association with prognosis of breast cancer patients. Two sets of patient samples (45 fresh tissues and 373 paraffin‑embedded tissues) were analyzed for RASA1 expression using RT‑qPCR and immunohistochemistry. The results showed that the expression of RASA1 mRNA was lower in breast cancer tissues than in the corresponding normal tissues (P<0.001). Additionally, RASA1 expression was reduced in 60.6% (226/373) of breast cancer tissues. The reduced RASA1 expression was significantly associated with tumor lymph node metastasis (P=0.002), advanced TNM stages (P=0.017), estrogen receptor (ER) expression (P=0.002), Ki‑67 (P=0.009), higher histological grade (P<0.001), and triple‑negative breast cancer (P=0.041). Moreover, the reduced RASA1 expression was associated with shorter disease‑free survival (P=0.036) and overall survival (P<0.001) of breast cancer patients. RASA1 expression, together with tumor lymph‑node metastasis, TNM stage, Her‑2 expression, and triple‑negative breast cancer were independent factors in predicting survival of breast cancer patients. In conclusion, RASA1 expression is frequently reduced in breast cancer tissues, and the reduced RASA1 expression is associated with breast cancer progression and poor survival and disease‑free survival of patients.

View Figures

View References

1	Al-Mubarak M, Sacher AG, Ocana A, Vera-Badillo F, Seruga B and Amir E: Fulvestrant for advanced breast cancer: a meta-analysis. Cancer Treat Rev. 39:753–758. 2013. View Article : Google Scholar : PubMed/NCBI
2	Lianidou ES, Mavroudis D and Georgoulias V: Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer. 108:2426–2432. 2013. View Article : Google Scholar : PubMed/NCBI
3	Lavigne E, Holowaty EJ, Pan SY, et al: Breast cancer detection and survival among women with cosmetic breast implants: systematic review and meta-analysis of observational studies. BMJ. 346:Apr 29–2013.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
4	Stites EC and Ravichandran KS: A systems perspective of ras signaling in cancer. Clin Cancer Res. 15:1510–1513. 2009. View Article : Google Scholar : PubMed/NCBI
5	Saxena N, Lahiri SS, Hambarde S and Tripathi RP: RAS: target for cancer therapy. Cancer Invest. 26:948–955. 2008. View Article : Google Scholar : PubMed/NCBI
6	Liu YF, Deth RC and Devys D: SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes. J Biol Chem. 272:8121–8124. 1997. View Article : Google Scholar : PubMed/NCBI
7	Vigil D, Cherfils J, Rossman KL and Der CJ: Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 10:842–857. 2010. View Article : Google Scholar : PubMed/NCBI
8	Pamonsinlapatham P, Hadj-Slimane R, Lepelletier Y, et al: p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling. Biochimie. 91:320–328. 2009. View Article : Google Scholar
9	Hu X, Stern HM, Ge L, et al: Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 7:511–522. 2009. View Article : Google Scholar : PubMed/NCBI
10	Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327. 2005. View Article : Google Scholar : PubMed/NCBI
11	Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
12	Aksoy S, Dizdar O, Harputluoglu H and Altundag K: Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. Ann Oncol. 18:1904–1906. 2007. View Article : Google Scholar : PubMed/NCBI
13	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
14	Xue C, Wang X, Peng R, et al: Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci. 103:1679–1687. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Cheng S, Zhang G, et al: Low expression of RECK indicates a shorter survival for patients with invasive breast cancer. Cancer Sci. 103:1084–1089. 2012. View Article : Google Scholar : PubMed/NCBI
16	Liu T, Zhang X, Shang M, et al: Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol. 107:188–194. 2013. View Article : Google Scholar
17	Adam Maciejczyk A: New prognostic factors in breast cancer. Adv Clin Exp Med. 22:5–15. 2013.PubMed/NCBI
18	do Carmo França-Botelho A, Ferreira MC, França JL, França EL and Honorio-França AC: Breastfeeding and its relationship with reduction of breast cancer: a review. Asian Pac J Cancer Prev. 13:5327–5332. 2012. View Article : Google Scholar
19	Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
20	Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
21	Cadoo KA, McArdle O, O’Shea AM, Power CP and Hennessy BT: Management of unusual histological types of breast cancer. Oncologist. 17:1135–1145. 2012. View Article : Google Scholar : PubMed/NCBI
22	Henkemeyer M, Rossi DJ, Holmyard DP, et al: Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature. 377:695–701. 1995. View Article : Google Scholar : PubMed/NCBI
23	Lapinski PE, Bauler TJ, Brown EJ, Hughes ED, Saunders TL and King PD: Generation of mice with a conditional allele of the p120 Ras GTPase-activating protein. Genesis. 45:762–767. 2007. View Article : Google Scholar : PubMed/NCBI
24	Sun D, Yu F, Ma Y, et al: MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem. 288:9508–9518. 2013. View Article : Google Scholar : PubMed/NCBI
25	Trahey M, Wong G, Halenbeck R, et al: Molecular cloning of two types of GAP complementary DNA from human placenta. Science. 242:1697–1700. 1988. View Article : Google Scholar : PubMed/NCBI
26	Moran MF, Koch CA, Anderson D, et al: Src homology region 2 domains direct protein-protein interactions in signal transduction. Proc Natl Acad Sci USA. 87:8622–8626. 1990. View Article : Google Scholar : PubMed/NCBI
27	Musacchio A, Gibson T, Rice P, Thompson J and Saraste M: The PH domain: a common piece in the structural patchwork of signalling proteins. Trends Biochem Sci. 18:343–348. 1993. View Article : Google Scholar : PubMed/NCBI
28	Clark JD, Lin LL, Kriz RW, et al: A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell. 65:1043–1051. 1991. View Article : Google Scholar : PubMed/NCBI
29	Gawler DJ, Zhang LJ, Reedijk M, Tung PS and Moran MF: CaLB: a 43 amino acid calcium-dependent membrane/phospholipid binding domain in p120 Ras GTPase-activating protein. Oncogene. 10:817–825. 1995.PubMed/NCBI
30	Glennon TM, Villa J and Warshel A: How does GAP catalyze the GTPase reaction of Ras? A computer simulation study. Biochemistry. 39:9641–9651. 2000. View Article : Google Scholar : PubMed/NCBI
31	Shurki A and Warshel A: Why does the Ras switch ‘break’ by oncogenic mutations? Proteins. 55:1–10. 2004. View Article : Google Scholar : PubMed/NCBI
32	Denhardt DT: Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J. 318:729–747. 1996.PubMed/NCBI
33	Cailliau K, Browaeys-Poly E and Vilain JP: RasGAP is involved in signal transduction triggered by FGF1 in Xenopus oocytes expressing FGFR1. FEBS Lett. 496:161–165. 2001. View Article : Google Scholar : PubMed/NCBI
34	Calvisi DF, Ladu S, Conner EA, et al: Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol. 54:311–319. 2011. View Article : Google Scholar :